iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer

October 28, 2009
Gaylord National Hotel and Convention Center
Washington, D.C.

Program Schedule

To view slides from a presenter, click the  icon next to their name.

Wednesday, October 28
7:45 am - 7:50 am	Welcome and Introduction Bernard A. Fox, PhD - Earle A. Chiles Research Institute
7:50 am - 8:00 am	Biomarkers and the Critical Pathway Initiative Samir Khleif, MD - National Cancer Institute
8:00 am - 8:15 am	FDA Perspective on Biomarkers  Steven Kozlowski, MD - Food and Drug Administration, Office of Biotechnology Products
8:15 am - 8:25 am	The Biomarkers Consortium: A Public-Private Partnership to Advance Biomarker Research  Shawnmarie Mayrand-Chung, PhD, JD - National Institutes of Health - Office of the Director, OPSA Public-Private Partnerships Program
8:25 am - 10:30 am	Session 1:   Standardization and Validation of Immunologic Biomarkers Co-Chairs:     Mary (Nora) Disis, MD - University of Washington                       Sylvia Janetzki, MD - ZellNet Consulting
8:25 am - 8:55 am	Standardization of Immune Biomarkers: Lessons from the HIV Field  Alan L. Landay, PhD - Rush University Medical Center
8:55 am - 9:15 am	Immune Monitoring Consortium Experience  Mary (Nora) Disis, MD - University of Washington
9:15 am - 9:25 am	Multi-Institution Trials and the Eastern Cooperative Oncology Group  Lisa H. Butterfield, PhD - University of Pittsburgh
9:25 am - 10:30 am	Discussion Moderator:     Sylvia Janetzki, MD - ZellNet Consulting Discussants:  Cedrik Britten, MD - Johannes Gutenberg University                        Dominic Eisinger, PhD - Rules Based Medicine, Inc.
10:30 am - 10:50 am	Break
10:50 am - 12:50 pm	Session 2:   Determining Potency of Immunologic Therapy Co-Chairs:     A. Karolina Palucka, MD, PhD - Baylor Institute for Immunology Research                       Theresa Whiteside, PhD - University of Pittsburgh Cancer Institute
10:50 am - 11:10 am	Assessing Dendritic Cell Vaccines  A. Karolina Palucka, MD, PhD - Baylor Institute for Immunology Research
11:10 am - 11:30 am	Mechanisms of Immune Suppression and Regulatory T Cells Theresa Whiteside, PhD - University of Pittsburgh Cancer Institute
11:30 am - 11:50 am	Use of Molecular Assays to Assess Cellular Therapies  David Stroncek, MD - Cell Processing, DTM, CC, National Institutes of Health
11:50 am - 12:50 pm	Discussion Moderator:     Licia Rivoltini, MD - Fondazione IRCCS Istituto Nazionale dei Tumori Discussant:    Edwin Walker, PhD - Providence Cancer Center
12:50 pm - 1:20 pm	Lunch
1:20 pm - 3:20 pm	Session 3:   Assessing the Immunologic Signature of Clinical Response Co-Chairs:     Cedrik M. Britten, MD - Johannes Gutenberg University                       Vernon C. Maino, PhD - BD Biosciences
1:20 pm - 1:40 pm	T Cell Response Signatures in Breast Cancer vs. Chronic Infection  Holden T. Maecker, PhD - Stanford University Medical Center
1:40 pm - 2:00 pm	Immunity to Glycolipid and Stem Cell Antigens in Human Cancer Madhav Dhodapkar, MD - Yale University
2:00 pm - 2:20 pm	Summary of the US-Japan Workshop on Immunotherapy Markers in Oncology  Hideaki Tahara, MD, PhD - University of Tokyo
2:20 pm - 3:20 pm	Discussion Moderator:     Lupe G. Salazar, MD - University of Washington Discussant:    Keith Bahjat, PhD - Earle A. Chiles Research Institute
3:20 pm - 3:45 pm	Break
3:45 pm - 4:45 pm	Session 4:   Centralization of Immunologic Monitoring Co-Chairs:     Alan L. Landay, PhD - Rush University Medical Center                       Anatoli M. Malyguine, MD, PhD - SAIC-Frederick, NCI-Frederick
3:45 pm - 3:55 pm	Immunologic Monitoring of Cancer Vaccine Trials - What to Measure, How and Why?  Anatoli M. Malyguine, MD, PhD - SAIC-Frederick, NCI-Frederick
3:55 pm - 4:25 pm	System Biology Approaches  Rafick-Pierre Sékaly, PhD - University of Montreal, VGTI Florida
4:25 pm - 4:45 pm	Some Statistical Issues in the Design and Analysis of Vaccine Clinical Trials in Cancer Patients  Douglas M. Potter, PhD - University of Pittsburgh
4:45 pm - 7:00 pm	Session 5:   Novel Marker Identification Co-Chairs:     Peter P. Lee, MD - Stanford University                       Francesco Marincola, MD - National Institutes of Health
4:45 pm - 5:00 pm	High Throughput Technology and Predictive Immune Monitoring  Peter P. Lee, MD - Stanford University
5:00 pm - 5:20 pm	Systems Immunology at the Bedside  Damien Chaussabel, PhD - Baylor Institute for Immunology Research
5:20 pm - 5:40 pm	Trans-NIH Center for Human Immunology: Goals and Progress  Giorgio Trinchieri, MD - National Cancer Institute
5:40 pm - 6:20 pm	Application of Proteomics to Biomarker Discovery: New Challenges, New Technology  Lance Liotta, MD, PhD - George Mason University
6:20 pm - 7:00 pm	Defining Immunologic Health Mark M. Davis, PhD - Howard Hughes Medical Institute / Stanford University School of Medicine
7:00 pm	Networking Reception

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.